Lansoprazole (AG 1749) is an oral proton pump inhibitor that effectively suppresses gastric acid secretion. Additionally, Lansoprazole (AG 1749) demonstrates potent inhibition of neutral sphingomyelinase (N-SMase), making it a brain-penetrant exosome inhibitor[1][2].
体内研究
Lansoprazole treatmentat doses ranging from 20 to 40 mg/kg significantly reduced memory deficits and attenuated biochemical and histopathological alterations induced by STZ and HFD[3].
Lansoprazole administered orally at doses of 20 mg/kg and 40 mg/kg significantly decreases the STZ and HFD-induced elevation in AChE activity[3].
Lansoprazole, administered orally at doses of 20 mg/kg and 40 mg/kg, significantly reduces the STZ and HFD-induced increase in brain MPO level[3].
HFD-fed mice treated with lansoprazole (20 mg/kg and 40 mg/kg, orally) exhibit a significant reduction in body weight compared to the control animals[3].
体外研究
Lansoprazole inhibits gastric acid secretion in a concentration-dependent manner, with an IC50 value of 0.76 μM, over a range of 0.3 to 3 μM[4].
Lansoprazole induces concentration-dependent, reversible, and reproducible relaxations of arteries within the range of 30 to 300 μM[5].
搜索
